CA2505873A1 - Derives quinoliniques - Google Patents

Derives quinoliniques Download PDF

Info

Publication number
CA2505873A1
CA2505873A1 CA002505873A CA2505873A CA2505873A1 CA 2505873 A1 CA2505873 A1 CA 2505873A1 CA 002505873 A CA002505873 A CA 002505873A CA 2505873 A CA2505873 A CA 2505873A CA 2505873 A1 CA2505873 A1 CA 2505873A1
Authority
CA
Canada
Prior art keywords
quinoline
piperidin
methyl
ethyl
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002505873A
Other languages
English (en)
Inventor
Bishop Wlodecki
Gene Michael Bright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2505873A1 publication Critical patent/CA2505873A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, d'une part des composés représentés par la formule (I) dans laquelle R?1¿, R?2¿, R?3¿, R?4¿ et n sont tels que décrits dans les spécifications, et d'autre part des sels pharmaceutiquement admis de ces composés. Les composés représentés par la formule (I), qui font preuve d'une activité d'agoniste par rapport aux récepteurs 5HT7, s'adressent particulièrement au traitement de troubles pouvant se traiter par une modulation des rythmes circadiens.
CA002505873A 2002-11-12 2003-10-31 Derives quinoliniques Abandoned CA2505873A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42551802P 2002-11-12 2002-11-12
US60/425,518 2002-11-12
PCT/IB2003/004903 WO2004043929A1 (fr) 2002-11-12 2003-10-31 Derives quinoliniques

Publications (1)

Publication Number Publication Date
CA2505873A1 true CA2505873A1 (fr) 2004-05-27

Family

ID=32313003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002505873A Abandoned CA2505873A1 (fr) 2002-11-12 2003-10-31 Derives quinoliniques

Country Status (7)

Country Link
EP (1) EP1562908A1 (fr)
JP (1) JP2006508113A (fr)
AU (1) AU2003274551A1 (fr)
BR (1) BR0316164A (fr)
CA (1) CA2505873A1 (fr)
MX (1) MXPA05005111A (fr)
WO (1) WO2004043929A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
GB201320905D0 (en) * 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
EP3337497B1 (fr) 2015-08-21 2023-07-12 SRX Cardio, LLC Composition et procédés d'utilisation de nouveaux petits composés organiques de phénylalanine pour moduler directement l'activité de la protéine pcsk9
WO2017034997A1 (fr) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Modulateurs phénylpipérazine proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et leur utilisation
WO2017034990A1 (fr) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition et procédés d'utilisation de petites molécules de type tétrahydroisoquinoline pour se lier à pcsk9 et moduler l'activité protéique de pcsk9
CA3005766A1 (fr) 2015-12-17 2017-06-22 Merck Patent Gmbh Antagonistes de tlr7/8 polycyliques et leur utilisation dans le traitement de maladies immunes
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
EP3484874B1 (fr) * 2016-07-14 2020-04-29 Bristol-Myers Squibb Company Composés monocycliques hétéroaryl substituées
JP7125385B2 (ja) * 2016-08-08 2022-08-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｌｒ７／８アンタゴニストおよびそれらの使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE812911C (de) * 1945-03-12 1951-09-06 Rhone Poulenc Sa Verfahren zur Herstellung von neuen substituierten Derivaten des Piperidins
FR2560873B1 (fr) * 1984-03-09 1986-09-26 Rhone Poulenc Sante Medicaments a base de derives de la piperidine, nouveaux derives de la piperidine et leurs procedes de preparation

Also Published As

Publication number Publication date
BR0316164A (pt) 2005-09-27
JP2006508113A (ja) 2006-03-09
MXPA05005111A (es) 2005-07-01
AU2003274551A1 (en) 2004-06-03
WO2004043929A1 (fr) 2004-05-27
EP1562908A1 (fr) 2005-08-17

Similar Documents

Publication Publication Date Title
US6462048B2 (en) Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors
CA3087912A1 (fr) Promedicaments a base de ketamine, compositions et utilisations de ceux-ci
KR101961851B1 (ko) 피리다지논 화합물 및 이들의 daao 저해제로서의 용도
US20220110923A1 (en) Esters and carbamates as modulators of sodium channels
US20040072867A1 (en) NK1 antagonists
PT701819E (pt) Novas composicoes contendo sertralina e um agonista ou antagonista de receptor de 5-ht1d
WO2006090273A2 (fr) [1,8]naphthyridin-2-ones et composes relatifs a liants ceto ou hydroxyl destines au traitement de la schizophrenie
WO2005047286A1 (fr) Compose spiranique heterocyclique
CA2564994A1 (fr) Composes de morpholine substitues permettant de traiter des troubles du systeme nerveux central
JP2010515769A (ja) 疼痛を治療するためのモルホリンドーパミン作動薬
JPH04270219A (ja) 胃酸分泌阻害物質
JP2011513394A (ja) ムスカリン受容体アゴニスト、組成物、処置方法及びその製造方法
JP2022547079A (ja) てんかんを治療する方法を使用しててんかんを治療する方法
CA2505873A1 (fr) Derives quinoliniques
AU2019234858A1 (en) Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds
KR20030059327A (ko) 벤질 (이덴)-락탐 및 5ｈｔ1-수용체 리간드로서의 그의 용도
JP2024520643A (ja) ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
US20040229874A1 (en) 5HT7 Antagonists and inverse agonists
TWI303246B (en) Fused ring nk1 antagonists
EA015974B1 (ru) Производные пирролизина, индолизина и хинолизина, их получение и их применение в терапии
US6894062B1 (en) Quinoline derivatives
US7381741B2 (en) 3-amino-2-phenylpyrrolidine derivatives
US20120232118A1 (en) Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
JP2010189275A (ja) ナフタレン誘導体
US20060030566A1 (en) Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead